Showing 621 - 640 results of 3,305 for search '"labelling"', query time: 0.06s Refine Results
  1. 621

    Prevention of Acute Radiation-Induced Skin Reaction with NPE® Camellia Sinensis Nonfermentatum Extract in Female Breast Cancer Patients Undergoing Postoperative Radiotherapy: A Single Centre, Prospective, Open-Label Pilot Study by Gabriela Näf, Urs E. Gasser, Hans E. Holzgang, Sandra Schafroth, Christoph Oehler, Daniel R. Zwahlen

    Published 2018-01-01
    “…Twenty patients were enrolled in this single centre, prospective, open-label pilot study. The outcomes of 20 prospective data sets were compared with 100 retrospectively collected matched data sets derived from hospital records. …”
    Get full text
    Article
  2. 622
  3. 623
  4. 624
  5. 625
  6. 626
  7. 627
  8. 628
  9. 629
  10. 630
  11. 631
  12. 632
  13. 633
  14. 634
  15. 635

    Combined use of respiratory multiplex PCR and procalcitonin to reduce antibiotic exposure in sickle-cell adult patients with acute chest syndrome (The ANTIBIO-STA study): a randomised, controlled, open-label trialResearch in context by Alexandre Sabaté-Elabbadi, Armand Mekontso-Dessap, François Lionnet, Aline Santin, Charlotte Verdet, Paul-Louis Woerther, Julien Lopinto, Matthieu Turpin, Alexandra Rousseau, Romane Lacoste-Badie, Keyvan Razazi, Guillaume Voiriot, Muriel Fartoukh

    Published 2025-04-01
    “…Methods: We conducted a randomised, controlled, parallel group, open-label study in two French hospitals. Consecutive adult patients with ACS were randomly assigned to the conventional or interventional strategy, where antibiotic therapy was targeted on the results of mPCR performed on lower respiratory tract secretions (LRTS) samples, and antibiotic discontinuation based on PCT values and kinetics at Day 1 (D1), D3 and D7. …”
    Get full text
    Article
  16. 636
  17. 637
  18. 638
  19. 639

    Efficacy and safety of NeoAdjuvant chemotherapy with or without tIslelizumab followed by debulking surgery for oVarian cancEr (NAIVE study) in China: study protocol of an open-label, phase II, randomised controlled trial by Ying Zhu, Jianwei Zhou, Zhigang Zhang, Jiaojiao Zhang, Jing Fei, Xiaoqing Zhu

    Published 2025-02-01
    “…The NeoAdjuvant chemotherapy with or without tIslelizumab followed by debulking surgery for oVarian cancEr(NAIVE) study aims to assess the clinical efficacy and safety of NACT in combination with tislelizumab (a monoclonal antibody for programmed cell death protein 1) for advanced EOC.Methods and analysis The NAIVE study is an investigator-initiated, prospective, single-centre, open-label, randomised controlled trial for advanced EOC with the International Federation of Gynaecology and Obstetrics (FIGO) stage IIIc with a Suidan CT score of 3 or greater or a Fagotti laparoscopic score of 8 or greater; or FIGO stage IV. …”
    Get full text
    Article
  20. 640